Heidelberg, Germany, 2 October, 2006. Privately-held Heidelberg Pharma GmbH has raised 16 million EUR (20 million USD) in a series B-Round subscribed by existing shareholders. HDP Beteiligungs GmbH, as the major shareholder, increased its stake in Heidelberg Pharma GmbH to approximately 86 % with a cash contribution of 16 million EUR or 20 million USD. Including the earlier series A-round, Heidelberg Pharma has now raised a total of 41 million EUR or 52 million USD. HDP-Beteiligungs GmbH, advised by Dievini GmbH, represents the interests of Dietmar Hopp and his family. Dietmar Hopp is the founder and former CEO of SAP AG.
The financing will allow Heidelberg Pharma to continue its ongoing clinical development programs. Proceeds will be used to confirm the positive preliminary phase II findings with Heidelberg Pharma's lead-compound Fosfluridine for the systemic treatment of Actinic Keratosis, as well as to continue the ongoing phase II trials of its anti-HIV drug Fosalvudine against resistant HIV viruses, and to fund promising pipeline-projects like EPD-Clofarabine.
In a shareholder meeting on August 29, 2006, the legal form of the company was changed to a corporation (Aktiengesellschaft) and the share capital was increased to 8,722,000 shares issued with a nominal value of 1EUR each. This change will become legally effective after registration in the "Handelsregister".
Dr. Jan Schmidt-Brand, CEO of Heidelberg Pharma, stated: " We are happy to see that our efforts and the milestones met, confirm the confidence of our investors in Heidelberg Pharma. The new proceeds will allow us to develop our portfolio beyond proof-of-concept of the most advanced projects and to further mature and build our pipeline".
Prof. Dr. Christof Hettich, Chairman of the Supervisory Board of Heidelberg Pharma added: "The new legal form will provide Heidelberg Pharma with the necessary strategic flexibility for further successful development of the company."
Heidelberg Pharma GmbH Heidelberg Pharma GmbH is a pure-play drug-development company, dedicated to the development of patented drugs which are more effective and better tolerated in the disease areas of cancer and HIV. Heidelberg Pharma currently has three drug candidates under clinical development.
Please contact:
Heidelberg Pharma GmbH Dr. Marcel Linssen Senior VP Corporate Development & Marketing Certified Investor Relations Officer Phone: +49 6203 1009 40 [email protected]
MC Services AG Raimund Gabriel Phone: +49 89 210 2280 [email protected]
